Those who receive the COVID-19 vaccine during pregnancy are less likely to be hospitalized for COVID-19; however, vaccine uptake in this population is suboptimal.

Emotional dysregulation is more severe among individuals with ASD than neurotypical peers and those with other clinical conditions.

The mRNA-1273 COVID-19 booster dose was safe and elicited robust immune responses among children aged 6 months to 5 years and 6 to 11 years.

Childhood attention-deficit/hyperactivity disorder (ADHD) is associated with impaired cognitive functioning in adulthood.

Influenza vaccination in successive pregnancies is not associated with increased risk for prespecified adverse perinatal outcomes.

COVID-19 vaccination was associated with a lower incidence of mental illnesses, like depression, following COVID-19 infection.

Ketamine treatment among patients with fibromyalgia may offer short-term pain relief, though its long-term efficacy and safety remain uncertain.

Following COVID-19 vaccination, most patients with MS do not face an increased risk for relapse requiring corticosteroid therapy.

A mailed knowledge mobilization and behavior change intervention can reduce the use of sedatives and improve sleep outcomes in older adults with insomnia.

The use of SGLT2 inhibitors vs DDP-4 inhibitors is associated with a reduced risk of developing different types of dementia.

Parathyroidectomy vs nonoperative management was not associated with a reduced risk for depression among patients with hyperparathyroidism.

Frailty is an independent risk factor for increased rates of readmission and inpatient mortality among hospitalized patients with SLE.